Go or no go? Covid-19 upstages US regulatory decisions

Regulatory delays are growing ever more likely as the threat of coronavirus ramps up globally. The US FDA announced earlier this month that it was postponing certain manufacturing facility inspections, and some advisory committee meetings have been cancelled; drug approvals are surely next to be hit.

Vantage took a look at US regulatory decisions remaining for this month and those expected in April − bellwethers for the future regulatory landscape.